Skip to content
Clinical Trials – home

Centrum Diagnostyki I Mikrochirurgii Oka Lens Sp. z o.o.

Research site

Poland Ul. Budowlana 3a, 10-424 Olsztyn, Poland

  • 7 trials recruiting
  • Neovascular age-related macular degeneration · Diabetic retinal oedema · Age-related macular degeneration
  • Adult patients

About Specializations

Centrum Diagnostyki I Mikrochirurgii Oka Lens Sp. z o.o. in Olsztyn, Poland specialises in clinical trials of conditions such as Neovascular age-related macular degeneration, Diabetic retinal oedema, Age-related macular degeneration, Dry age-related macular degeneration, and other specialisations. This site conducts important research.

Main research areas of the site

Eye Diseases

The centre concentrates on eye diseases such as age‑related macular degeneration, diabetic macular edema, and retinal vein occlusion. Clinical studies are designed to evaluate new therapies, compare existing treatments, and improve visual acuity for affected patients.

  • Age‑related macular degeneration (wet and dry)
  • Diabetic macular edema
  • Diabetic retinopathy
  • Retinal vein occlusion
  • Myopic choroidal neovascularization

Centrum Diagnostyki I Mikrochirurgii Oka Lens supports a multidisciplinary team of five investigators conducting fifteen trials, emphasizing patient‑centered care and advancing ophthalmic research in Olsztyn, Poland.

Ocular Physiological Phenomena

Research also explores ocular physiological phenomena such as retinal fluid dynamics and complement system activity, seeking to understand disease mechanisms and assess how novel agents influence visual function and disease biomarkers.

  • Complement pathway inhibition studies
  • Dosing frequency‑response evaluations
  • Innovative drug‑delivery systems
  • Pre‑filled syringe usability assessments
  • Port delivery system performance

Located in Olsztyn, the site collaborates with local healthcare professionals to ensure rigorous trial conduct and high‑quality data collection for advancing eye‑health science.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Budowlana 3a10-424 OlsztynPoland
Recruiting now
7 trials
Conditions studied
10

More sites in OlsztynPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

22 clinical trials

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide
  • Sponsor:ONL Therapeutics Inc.

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 1815368
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of oral STL303 hydrochloride to assess safety and effectiveness in adults with geographic atrophy secondary to age‑related macular degeneration

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Safety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:65+ years
  • Substances:Aflibercept

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.